RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.

Man-Fung YuenIngolf SchiefkeJung-Hwan YoonSang Hoon AhnJeong HeoJu Hyun KimHenry Lik Yuen ChanKi Tae YoonHartwig KlinkerMichael MannsJoerg PetersenThomas SchluepJames HamiltonBruce D GivenCarlo FerrariChing-Lung LaiStephen A LocarniniRobert G Gish

Published in: Hepatology (Baltimore, Md.) (2020)

ARC-520 was active in both E-neg and E-pos, NUC-experienced HBV patients; but absolute HBsAg reductions were moderate, possibly due to expression of HBsAg from integrated HBV DNA, indicating the need for RNAi therapeutics that can target viral transcripts regardless of origin.

Keyphrases

hepatitis b virus
end stage renal disease
liver failure
ejection fraction
chronic kidney disease
newly diagnosed
poor prognosis
sars cov
prognostic factors
small molecule
high intensity
cell free
patient reported outcomes
nucleic acid
smoking cessation